NBResearcher profile · from public sources
Nizar J Bahlis
Targets
Filled chips are declared by the researcher; the others come from publications (number of works).
Now
Trials, publications and grants since Nov 2024.
Publication
Modeling Long-Term Progression-Free Survival in Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Nov 2026
Publication
Author Correction: FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial.
Nature medicine, Oct 2026
Publication
MAIA frailty subgroup analysis: long-term follow-up with daratumumab plus lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma.
Leukemia, Oct 2026
Publication
Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Transplant-Ineligible Subgroup Analysis of CEPHEUS.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Sept 2026
Publication
Teclistamab and Daratumumab Immune-Based Doublet Therapy for Relapsed/Refractory Multiple Myeloma: the TRIMM-2 Study.
Blood advances, Sept 2026
Publication
Daratumumab in transplant-ineligible or -deferred newly diagnosed multiple myeloma: minimal residual disease in CEPHEUS.
Blood advances, Aug 2026
Publication
Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis.
Leukemia, Aug 2026
Publication
Daratumumab plus bortezomib, lenalidomide, and dexamethasone in transplant-deferred newly diagnosed multiple myeloma: Frailty subgroup analysis of CEPHEUS.
Leukemia, Aug 2026
Publication
FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial.
Nature medicine, Jul 2026
Publication
Infections in patients receiving daratumumab for newly diagnosed multiple myeloma: a pooled analysis of MAIA and ALCYONE.
Blood advances, Jul 2026
Publication
The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D.
Leukemia, Feb 2026
Publication
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma.
Nature medicine, Jan 2026
Preprint
Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myeloma.
bioRxiv : the preprint server for biology, Dec 2025
Publication
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Dec 2025
Publication
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.
The New England journal of medicine, Dec 2025
Publication
Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell-Redirecting Immunotherapies.
Blood cancer discovery, Nov 2025
Publication
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Jun 2025
Publication
Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.
Nature medicine, Feb 2025
Publication
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study.
Leukemia, Jan 2025
Publication
Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma.
Blood, Dec 2024
Publication
Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses.
Blood, Dec 2024
Publication
Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies.
Blood, Dec 2024
Co-authors
Who links you
Enter another researcher's profile link or ID to see who has published with both of you.
You have published with Shinsuke Iida directly.
Is this you? Request a correction or removal: support@frontlightresearch.com
Report an error